Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib
Phase of Trial: Phase IV
Latest Information Update: 11 Sep 2019
Price : $35 *
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms TRASTYVERE
- 06 Sep 2019 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 12 Dec 2014 Status changed from recruiting to active, no longer recruiting according to results presented at the 37th Annual San Antonio Breast Cancer Symposium.